The relationship between long-term cholinergic dysfunction and risk of developing dementia is poorly understood. Here we used mice with deletion of the vesicular acetylcholine transporter (VAChT) in the forebrain to model cholinergic abnormalities observed in dementia. Whole-genome RNA sequencing of hippocampal samples revealed that cholinergic failure causes changes in RNA metabolism. Remarkably, key transcripts related to Alzheimer's disease are affected. BACE1, for instance, shows abnormal splicing caused by decreased expression of the splicing regulator hnRNPA2/B1. Resulting BACE1 overexpression leads to increased APP processing and accumulation of soluble Aβ 1-42 . This is accompanied by age-related increases in GSK3 activation, tau hyperphosphorylation, caspase-3 activation, decreased synaptic markers, increased neuronal death, and deteriorating cognition. Pharmacological inhibition of GSK3 hyperactivation reversed deficits in synaptic markers and tau hyperphosphorylation induced by cholinergic dysfunction, indicating a key role for GSK3 in some of these pathological changes. Interestingly, in human brains there was a high correlation between decreased levels of VAChT and hnRNPA2/B1 levels with increased tau hyperphosphorylation. These results suggest that changes in RNA processing caused by cholinergic loss can facilitate Alzheimer's-like pathology in mice, providing a mechanism by which decreased cholinergic tone may increase risk of dementia.
Introduction
Alzheimer's disease (AD), the predominant form of dementia, is pathologically characterized by accumulation of amyloid plaques and neurofibrillary tangles that ultimately lead to neuronal death. One of the early alterations identified in AD-affected individuals with cognitive decline is a profound decrease in basal forebrain cholinergic neurons (Whitehouse et al. 1982) , which gave rise to the cholinergic hypothesis of AD (Bartus et al. 1982) . Accordingly, Alzheimer's Disease Neuroimaging Initiative data reveal atrophy of the basal forebrain in individuals with mild cognitive impairment (Grothe et al. 2014 ) and increased forebrain cholinergic atrophy in Alzheimer's-affected individuals (Grothe et al. 2013) . Cholinergic dysfunction correlates with decreased hippocampal volume and pathology (Teipel et al. 2014) . Furthermore, recent epidemiological data suggest that long-term use of drugs with anticholinergic activity by elderly individuals increases the future risk of dementia (Gray et al. 2015) . These observations reveal an intimate, but poorly understood relationship, between cholinergic dysfunction and the pathological and cognitive deficits in AD. However, whether cholinergic malfunction has a causal role in increasing the risk of dementia or regulating pathology is unknown. Moreover, the causal and temporal relationships between cholinergic malfunctioning and long-term changes in hippocampal neurons in AD are still unclear.
To test the capacity of cholinergic tone to regulate long-term functions in target cells, we examined the hippocampal transcriptome in genetically modified mice with compromised hippocampal cholinergic tone. Using forebrain-specific deletion of the vesicular acetylcholine transporter (VAChT), a protein required for acetylcholine (ACh) release (de Castro et al. 2009; Prado et al. 2013) , we unveil that long-term cholinergic deficiency causes global changes in gene expression and alternative splicing in the hippocampus. This leads to abnormal alternative splicing of BACE1 with consequent age-dependent changes in amyloid precursor protein (APP) processing, tau hyperphosphorylation, hippocampal neuronal loss, and cognitive decline. Comparative analyses in the AD brain enabled us to identify links between cholinergic deficiency and AD pathology, together supporting the notion that early cholinergic dysfunction may be a pivotal step in AD pathology initiation and progression. Our data provide potential mechanisms to explain how cholinergic deficiency may facilitate pathology in AD.
Materials and Methods

Mouse Lines
Generation of VAChT flox/flox mice was previously described (de Castro et al. 2009 ). VAChT Nkx2.1-Cre-flox/flox mice were generated by crossing VAChT flox/flox (crossed for 5 generations with C57BL/6J) with the Nkx2.1-Cre mouse line (C57BL/6J-Tg(Nkx2-1-cre)2Sand/J), purchased from The Jackson Laboratory (JAX stock no. 008661).
Unless otherwise stated, all control mice used were VAChT flox/flox
littermates. All procedures were conducted in accordance with guidelines of the Canadian Council of Animal Care (CCAC) and in accordance with ARRIVE guidelines, at the University of Western Ontario with an approved institutional animal protocol . Only male mice were used for all experiments.
RNA Sequencing
Mouse hippocampal tissue was rapidly dissected, and total RNA was extracted from individual samples using the PureLink RNA Mini Kit (Ambion). Two micrograms of total RNA were then sent to the Centre for Applied Genomics, The Hospital for Sick
Children, where the cDNA library was prepared using the TruSeq Stranded Total Sample Preparation kit (Illumina) and run in a HiSeq 2500 platform with coverage of 200-250 million pair reads per lane. Five animals were run per lane to obtain enough coverage for alternative splicing analysis (50 million pair reads per sample). The sequenced reads were aligned to the mouse genome using the TopHat program against the mouse genome in Ensembl (version EnsMart72) to enable quantification of splice junctions in addition to gene-level measurements. Differential gene expression analysis was conducted using the Bioconductor DESeq package which accounts for the counts binomial distribution (Anders and Huber 2010) . Datasets are available on ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) under accession number E-MTAB-3897. For human brains, we used the SQUARE™ RNA library construction approach that utilizes different sets of 5′-and 3′-site specific primers to segregate all full-length transcripts into subpools defined by the selective nucleotides in the respective primers. Unlike traditional sequencing, which is based on the use of universal primers that produce a pool of fragmented RNA products for a given gene, we used 12 different sets of 3′-primers that complement all distinct di-nucleotides at transcript 3′-polyadenylation sites and enable separate sequencing of the corresponding intact RNA molecules for each of the primer sets through barcoding. This unprecedented depth of segregated brain RNASeq data was made publicly accessible by establishing a user friendly website where the sequenced variants for any given brain-expressed transcript can be found (http://apainad.weebly. com/). Sequencing files were processed and analyzed for differential expression and functional enrichment.
RNA sequencing libraries made from the temporal gyrus samples yielded an average of 6.0 × 10 6 (STD = 2.0 × 10 6 ) uniquely aligned 75 base pair (bp) single end reads or approximately 7.0 × 10 7 (STD = 1.8 × 10 7 ) total read counts when combining all 12 SQUARE fields for each sample. These reads were mapped against the GRGCh37/hg19 version of the Homo sapiens genome (http://genome.ucsc.edu/). Transcripts with >1 read per kilobase per million (RPKM) per SQUARE field were defined as being detected (Hebenstreit and Teichmann 2011 ). An average of 6610 ± 1367 genes per field were detected across the 12 fields (details in Supplementary Table 3) . Expression criteria were set to RPKM > 1 in at least one of the SQUARE fields, in at least 80% of the tested donor cohorts.
Immunofluorescence
Immunofluorescence experiments were performed as previously described (de Castro et al. 2009 ). Primary antibodies used were anti-Cleaved caspase-3 (1:500 Thermo Fisher Scientific, Catalog no. PA5-16335), anti-AT180 (1:1000 Thermo Fisher Scientific, Catalog no. EN-MN1040), and anti-PSD95. Sections were visualized by Zeiss LSM 510 Meta (Carl Zeiss, Oberkochen, Germany) confocal system (×40, ×63 objectives, with an N.A. of 1.3 and 1.4, respectively) and by Leica TCS SP8 (Leica Microsystems Inc., Ontario, Canada) confocal system (×63 objective, with an N.A. of 1.4), a 488-nm Ar laser and 633-nm HeNe laser were used for excitation of fluorophores.
Western Blotting
Mouse hippocampi were collected, protein was isolated, and immunoblotting was performed as previously described using RIPA lysis buffer supplemented with protease and phosphatase inhibitors (Guzman et al. 2011) . Band intensities were quantified using FluoroChemQ software (Thermo Fisher Scientific).
Gene Ontology Analysis
Gene ontology functional analysis was performed using the GOrilla software through the web application. Using the 2 unranked lists method as described (Eden et al. 2009 ). KEGG pathway analysis was performed using the ClueGO plug-in of Cytoscape (Bindea et al. 2009 ).
RNA-Binding Protein Analysis
To predict potential RNA-binding proteins that may be implicated in the observed changes in alternative splicing, alternatively spliced sequences were run through the RBPmap software (Paz et al. 2014) to detect potentially altered RNA-binding proteins.
The list of RNA-binding proteins that were suggested by the software was then run through the Allen Brain Atlas (http://mouse. brain-map.org/) to ensure that they were expressed in the murine hippocampus. All RNA-binding proteins not expressed in the hippocampus were excluded.
qPCR
To measure mRNA expression, total RNA was extracted from freshly dissected hippocampal tissue, using the Aurum Total RNA for fatty and fibrous tissue kit (Bio-Rad) according to the manufacturer's instructions. cDNA synthesis and qPCR analysis were performed as previously described (Guzman et al. 2011) . For alternative splicing experiments, the alternative exon levels were normalized to a constitutively expressed exon from the same gene.
Primary Neuronal Cultures
Primary mouse hippocampal neurons were produced from E16 embryos as previously described (Ostapchenko et al. 2013 ). Neurons were cultured for 15 days. Knockdown of hnRNPA2/B1 from the cultured neurons was achieved by treatment with a shRNA, as previously described (Berson et al. 2012) . A separate set of cultured neurons was treated with 10 μM of carbachol, 10 μM of carbachol and 100 μM Atropine, or 100 μM Atropine alone for 48 h.
APP Processing
Biochemical analysis of the processing of APP was performed as previously described (Dewachter et al. 2002) . Forebrains from VAChT-deficient and control mice were homogenized in 50 mM Tris-HCl ( pH 8.5); samples were then ultracentrifuged at 135 000 × g for 1 h at 4°C; and the supernatant was collected and analyzed by western blotting and ELISA. The pellet was re-suspended and ultracentrifuged again and diluted in 8 M guanidine HCl to obtain the insoluble fraction for ELISA analysis.
ELISA
Murine β-amyloid was measured from the hippocampal homogenate using the Wako Human/Rat (Mouse) β-Amyloid (42) ELISA High-Sensitive Kit (Catalog Number: 292-64501). The ELISA assay was performed according to the manufacturer's protocol.
Congo Red Staining
Congo red staining was performed as previously described (Thompson and Walker 2015) , using a Congo Red solution (Sigma C-6277) in 100% ethanol.
Silver Staining
Assessment of argyrophilic cells in the hippocampus was done by using NeuroSilverTM staining kit II (FD NeuroTechnologies, Inc., Baltimore, MD, USA), which provides detection of degenerating neurons, including neuronal somata, axons, and terminals.
Estimation of Hippocampal Volume
NeuN immunohistochemistry was performed to estimate the volume of and number of neurons of hippocampal regions CA1, CA3, and the dentate gyrus (DG) as described (Beauquis et al. 2014) . Briefly, tissue sections were stained with mouse monoclonal anti-NeuN (1:500 PhosphoSolutions, Catalog no. 583-FOX3), using the ABC kit (Vector Laboratories) and developed with 2 mM diaminobenzidine (Sigma, USA) and 0.5 mM H 2 O 2 in 0.1 M Tris buffer. The total number of NeuN (T) cells in the various hippocampal regions was estimated using the following formula:
where N is the cell density, V is the volume of the structure, and t is the thickness of the section.
GSK3 Inhibition
To inhibit GSK3 in VAChT Nkx2.1-Cre-flox/flox mice, a cohort of aged animals (12 months old, n = 5 AR-A014418 treated, n = 4 saline treated) were implanted with Alzet micro-osmotic pumps (Model 1004; DURECT Corp, Cupertino, CA, USA). The pumps were implanted subcutaneously in the intrascapular region of each mouse. The reservoir of each pump was preloaded with 96 μL of either sterile saline solution or the GSK3 inhibitor AR-A014418. The pumps administered 5 mg/kg/day of AR-A014418, a dose shown to produce a significant inhibition of GSK3 in vivo (Ly et al. 2013) . During the implantation procedure, mice were anesthetized with ketamine (100 mg/kg) and xylazine (15 mg/kg). Drug treatment lasted for 28 days.
Morris Water Maze
The spatial version of the Morris water maze (MWM) was conducted as described previously to investigate spatial memory (Vorhees and Williams 2006; Martyn et al. 2012; Kolisnyk et al. 2013a) . Briefly, animals were given 4 training trials a day (90 s each) for 4 days, with a 15-min intertrial interval. If the mice did not find the platform after 90 s during the learning phase, they were gently directed to the platform. On the fifth day, memory was assessed via a probe trial (60 s), during which the platform is removed and time spent in the target quadrant is measured. The task was performed in a 1.5-m diameter pool with 25°C water. The platform was submerged 1 cm below the surface of the water, and spatial cues ( posters, streamers, and plastic props) were distributed around the pool. Sessions were recorded and analyzed using the ANY-Maze Software. The classification of search strategies mice employed during training was defined as previously described (Garthe et al. 2009 ). An experimenter blind to genotypes scored search strategies as follows: 1) thigmotaxis, characterized by maintaining close proximity to the wall (>70% trial within 10 cm of wall); 2) random search, illustrated by global swimming with no classified strategy; 3) scanning, characterized by a preference for the central pool area (>50% trial within 35 cm of pool center); 4) chaining, characterized by searching near the correct radial distance of the platform to the wall (>75% trial 20-50 cm from the pool center, <15% within 10 cm of wall, and <10% within 20 cm of pool center); 5) directed search, characterized by a preference for a passageway toward the platform or platform quadrant (>80% trial within a 50-cm-wide region from the start point to the platform); 6) focal search, characterized by a highly localized search near the platform (≥50% trial in a circular target zone with a 15-cm radius); and 7) direct swim, characterized by a maintained heading toward the platform (little to no deviation in path to reach platform from start point). Total block lengths were the sum of all blocks for 1 strategy and 1 mouse.
Protein Isolation from Human Postmortem Brain Tissue
Samples from parietal cortical tissues from age-/sex-matched controls (n = 6, 3 females and 3 males) and AD-affected individuals (n = 6, 3 females and 3 males), and information related to age and demographics have been previously published (Ostapchenko et al. 2013) . The samples were homogenized in RIPA buffer supplemented with protease inhibitor cocktail (Calbiochem), and Western blotting was performed as described above.
Statistical Analysis
Sigmastat 3.5 software was used for statistical analysis. Student's t-test was used for comparison between 2 experimental groups. Two-way ANOVA or 2-way ANOVA with repeated measures (RM) were used when >2 groups were compared.
Results
Forebrain Cholinergic Dysfunction Modifies Expression Levels of Hippocampal Transcripts and Alternative Splicing
To determine the contribution of cholinergic tone to the regulation of hippocampal transcript levels, we used VAChT Nkx2.1-Cre-flox/flox mice, a mouse line with selective deletion of the VAChT gene from forebrain regions, including the medial septum, which contains cholinergic neurons that project to the hippocampus. VAChT has been shown to be essential for ACh packaging and release (Prado et al. 2006; de Castro et al. 2009; Lima Rde et al. 2010) . Non-biased, whole-genome transcriptome RNA sequencing of hippocampal samples from 3 VAChT-deficient and 4 control mice yielded a total of 14 200 expressed genes. Comparative analysis revealed that 1098 genes were differentially expressed in VAChT Nkx2.1-Cre-flox/flox hippocampi compared with control mice (Fig. 1A ,B, FDR corrected P < 0.05). Of those, 763 genes were upregulated and 362 downregulated in the VAChT-deficient mice. In addition, a linear regression analysis on reciprocal junction pairs detected roughly 4% of hippocampal transcripts in VAChT Nkx2.1-Cre-flox/flox mice as alternatively spliced in high confidence compared with control mice. Equal proportion of exon inclusion and exclusion events was observed; mainly events of cassette exons were detected ( Fig. 1C) , suggesting widespread changes in several splicing regulation-related pathways and/or cellular mechanisms (Soreq et al. 2014) . We interrogated these differentially expressed/spliced genes for involvement in neuronal function and AD-like pathology. A number of genes involved in critical pathways including PI3K-Akt signaling pathway (a regulator of neuronal vulnerability (Gary and Mattson 2001; Endo et al. 2006) ), spliceosome regulation, and regulation of microtubule-based processes were identified using Gene Ontology (GO) KEGG pathway analysis ( Fig. 1D ; see Supplementary Table 1) . qPCR validation and correlation between changes observed in RNA-Seq and in an independent mouse cohort are shown in Supplementary Figure 1 for the different gene pathways and alternative splicing events. These results suggest that abnormal cholinergic signaling can effectively modulate several major gene pathways with potential to influence the function of target cells in the hippocampus.
We also performed small molecule RNA-Seq and additional miRNA microarray hybridization experiments and observed limited changes in miRNA expression in the hippocampus of VAChTdeficient mice (see Supplementary Fig. 2 ). VAChT Nkx2.1-Cre-flox/flox hippocampus showed a mature miRNA expression profile with only marginal differences from controls. Only 7 of 700 detectable miRNAs were differentially expressed, and of the 20 miRNAs most highly expressed in the hippocampus, comprising 82% of total counts, none were differentially expressed (see Supplementary Fig. 2 ). These findings point to alternative splicing and transcription, or changes in mRNA turnover, rather than miRNA, as potential main contributors to phenotypes in VAChT-deficient mice.
Cholinergic Deficit Triggers Abnormal BACE1 Alternative Splicing and APP Processing
One of the detected abnormally alternatively spliced genes in our database was the protease BACE1 ( Fig. 1D ), which is responsible for the cleavage of APP (Luo et al. 2001) . The predicted alternative splicing event in VAChT-deficient mice is expected to increase expression of BACE1-501, the active protein isoform (Mowrer and Wolfe 2008) . qPCR analysis validated the predicted splicing event and demonstrated increased exon 3/4 inclusion for BACE1 ( Fig. 2A) .
Bioinformatics analysis using the RBP-Map tool revealed an enrichment of binding sites for hnRNPA2/B1 in BACE1 mRNA. hnRNPA2/B1 is part of a family of RNA-binding proteins that regulate pre-mRNA splicing, trafficking, and maturation (Bekenstein and Soreq 2013) . Notably, AD-associated impairments in cholinergic signaling are accompanied by decreased expression of hnRNPA2/B1 protein in the AD cerebral cortex and in cholinergic impaired mice (Berson et al. 2012; Kolisnyk et al. 2013b ). Correspondingly, the hippocampus of VAChT Nkx2.1-Cre-flox/flox mice showed reduced hnRNPA2/B1 protein levels (Fig. 2B) . We then investigated whether hnRNPA2/B1 regulates BACE1 splicing by exposing primary hippocampal cultured neurons to lentiviruscarrying shRNA against hnRNPA2B1. Our results showed changes in BACE1 splicing similar to cholinergic deficiency (Fig. 2C ), directly implicating hnRNPA2/B1 in the regulation of BACE1 splicing.
To test for the role of cholinergic signaling and the different cholinergic receptors in mediating this splicing event, we treated cultured hippocampal neurons with the cholinergic mimetic carbachol. This treatment was able to decrease the proportion of BACE1-501. This decrease was blocked by cotreatment with the muscarinic antagonist atropine (Fig. 2D ). These data implicate muscarinic receptors in the regulation of BACE1 splicing. This splicing event in BACE1 predicts an increase in the levels of the mature BACE1 protein, and indeed, immunoblot analysis revealed a 2-fold increase of BACE1 levels in the hippocampus of VAChT-deficient mice (Fig. 2E) .
In late-onset AD, BACE1 expression is upregulated (Hebert et al. 2008) , and it is thought to contribute to age-dependent progression in AD pathology (Ly et al. 2013) . We therefore tested for changes in APP processing in VAChT Nkx2.1-Cre-flox/flox mice. Aged
VAChT-deficient mice (11-14 month old) displayed a modified pattern of Tris-soluble APP fragments (Fig. 2F ), similar to that of mouse models with APP/PS1 mutations (Oddo et al. 2003; Jankowsky et al. 2004) . In contrast, membrane-bound C-terminal fragments of APP (α and β CTFs), alterations of which can suggest impaired proteolytic processing of the protein (reviewed in (Selkoe 2000) ), were similar in VAChT-deficient mice and controls (Fig. 2G) . APP processing was not modified in aged Nkx2.1-Cre mice (see Supplementary Fig. 3A ), suggesting that this effect is due to cholinergic dysfunction rather than to Cre expression. We then assessed the levels of mouse amyloid peptides using an ELISA kit validated for both mouse and human Aβ peptides (Teich et al. 2013 ). The hippocampus of aged
VAChT
Nkx2.1-Cre-flox/flox mice showed increased levels of soluble mouse Aβ peptide compared with controls ( Fig. 2H ), reaching about one-third of the levels of those found in aged 5XFAD mouse model of AD, which is one of the most aggressive models of AD amyloidosis. In comparison, insoluble amyloid peptide was undetectable in the brains of VAChT-deficient mice, whereas it was highly abundant in the 5XFAD mice (Fig. 2H) . In addition, neither control nor VAChT-deficient mice displayed positive Congo red staining, unlike brain sections from 5XFAD mice, which exhibited numerous Congo red plaques (Fig. 2I ). These data indicate that although VAChT-deficient mice show increased levels of soluble Aβ peptides, they do not seem to accumulate in extracellular amyloid plaques. Indeed, the murine amyloid peptide is much less prone to aggregation than human Aβ due to 2 amino acid changes (Jankowsky et al. 2007 ).
Cholinergic Deficit Leads to Age-Dependent Hippocampal Tauopathy
In AD, increased levels of soluble Aβ peptides are thought to precede abnormal phosphorylation of the microtubule-associated protein tau (Iqbal et al. 2010) . Previous reports suggested that cholinergic activity and tau phosphorylation might be interrelated (Hellstrom-Lindahl 2000) . Therefore, we used immunofluorescence to assess levels of the AT180 tau epitope (T231/S235) in the hippocampus of VAChT-deficient mice. This phosphorylation-dependent antibody specific to pT231 has been shown to label approximately 70% of paired helical filaments (PHF) in AD brains (Goedert et al. 1994 ). Phosphorylation at this epitope reduces the binding of tau to microtubules potentially increasing its toxicity (Lim et al. 2008) . Immunofluorescence imaging revealed a robust increase of AT180 immunoreactivity in the hippocampus of VAChT Nkx2.1-Cre-flox/flox mice compared with aged-matched controls ( Fig. 3A ; 11-14 months old mice). To test whether the positive immunoreactivity of pTau in VAChTdeficient mice is associated with an induction of pathological tau, immunofluorescence with MC1 antibody was performed. Positive reactivity of conformation-dependent MC1 antibody depends on the proximity of N-terminal (aa 7-9) and C-terminal (313-333) amino acid sequences of tau, which is one of the earliest alterations of tau in AD (Wolozin et al. 1986; Weaver et al. 2000) . Immunostaining with MC1 revealed positive immunoreactivity in the hippocampus of aged cholinergic-deficient mice, but not in age-matched controls (Fig. 3B ).
In agreement with the immunofluorescence data, hippocampal extracts of VAChT Nkx2.1-Cre-flox/flox mice showed approximately 4-fold increases in pTau immunoreactive bands, including higher order oligomers detected with AT180, compared with controls (Fig. 3C,D) . On the other hand, total tau and pTauS262 levels were unmodified in VAChT-deficient mice (Fig. 3C,D) . Taken together, our data indicate that deletion of hippocampal VAChT induces hyperphosphorylation of tau and leads to tau pathological conformation as detected by MC1, both of which are consistently observed in AD. These data suggest the potential for neuronal toxicity due to cholinergic dysfunction.
Cholinergic Deficiency Exacerbates Age-Dependent Neuronal Vulnerability and Impaired Learning
Synaptic health is compromised in mouse models of AD, and synaptic loss is a consistent finding in AD-affected individuals (Klein 2006) . To examine synaptic integrity, we stained hippocampal sections with the synaptic marker PSD95. Aged VAChT Nkx2.1-Cre-flox/flox mice displayed hippocampal decreases in PSD95 immunoreactivity, increased microglial activation, and upregulation of inflammatory markers, in comparison to age-matched controls, suggesting large-scale synaptic dysfunction in these mutants (Fig. 4A-C) . These observations predict neuronal vulnerability; therefore, we stained brain sections with silver, which accumulates in neurons that are more vulnerable to neurodegeneration (DeOlmos and Ingram 1971). Aged VAChT-deficient mice presented intensified silver staining compared with controls; this increased silver staining was not observed in young VAChT-deficient mice (Fig. 4D,E) , suggesting that long-lasting decrease in cholinergic signaling may increase the vulnerability of hippocampal neurons. Parallel staining of hippocampal sections from aged 5XFAD mice compared with control mice performed as a positive control revealed similar increases in silver staining as that for VAChT-deficient mice (see Supplementary Fig. 4 ). Activated caspase-3, a marker of apoptosis, was augmented in young VAChT Nkx2.1-Cre-flox/flox mice compared with controls ( Fig. 4F) . However, aging significantly increased the number of activated caspase-positive cells in VAChT-deficient mice compared with controls (Fig. 4F) . Also, young VAChT-deficient mice showed no alteration in the number of NeuN-positive cells across all regions of the hippocampus ( Fig. 4G ; see Supplementary Fig. 4) ; while NeuN-positive cells in CA1 and CA3 region, but not dentate gyrus, were decreased in aged VAChT-deficient mice ( Fig. 4G ; see Supplementary Fig. 4 ), predicting functional implications for this aging-related hippocampal neuronal vulnerability. Thus, impaired cholinergic signaling induces global changes in transcript levels, followed by age-related exacerbation of synaptic and neuronal vulnerability.
To test whether long-lasting cholinergic failure may have agedependent consequences in cognitive function, we subjected aged (11-14 months old) VAChT-deficient mice to the MWM task. Young VAChT-deficient mice (3-6 months old) show little difference from controls in acquisition performance on the MWM task . In contrast, aged VAChT-deficient mice took significantly longer and swam a greater distance than age-matched controls to find the platform across the 4 days of acquisition (see Supplementary Fig. 4E,F) . Furthermore, aged VAChT-deficient mice used distinct strategy preferences to find the platform, indicating that their deteriorated performance was due to modified learning capacities. Briefly, the analysis of search strategies used by each animal was based on a fixed set of criteria (Fig. 4H) . At a young age, both controls and VAChT Nkx2.1-Cre-flox/flox mice predominantly used a more direct strategy to reach the platform (strategies 5/6/7, Fig. 4I ). In contrast, aged VAChT-deficient mice used random swimming predominantly as their strategy to acquire the task (strategy 2, Fig. 4I ), while aged control mice maintained the use of more direct strategies. Aged VAChT-deficient mice also exhibited deficits in the probe trial (see Supplementary Fig. 4G ). Taken together, these results suggest that long-term cholinergic deficiency in VAChT Nkx2.1-Cre-flox/flox mice led to progressive loss of neurons in the hippocampus that worsened spatial information acquisition and cognitive functioning.
Cholinergic-induced Age-Dependent Pathology Is Partially Mediated by GSK3 Activation
In addition to APP processing and tau hyperphosphorylation, we observed other critical biochemical pathways altered in response to cholinergic deficiency, including aberrant GSK3 signaling, which has also been shown to play multiple roles in AD (Gary and Mattson 2001; Endo et al. 2006) . As several genes that regulate the PI3-AKT pathway were upregulated in VAChT-deficient mice ( Fig. 1D ; see Supplementary Fig. 1 ), we tested for dysregulation of PI3-AKT signaling pathway in these mice by evaluating the phosphorylation status of the AKT protein and its downstream target GSK3. AKT presented decreased phosphorylation at residue Ser473, with unmodified Thr308 phosphorylation, in VAChT Nkx2.1-Cre-flox/flox hippocampus compared with controls ( Fig. 5A) . Additionally, GSK3α/β tyrosine phosphorylation, which reflects activation of GSK3, was increased in these mutants (Fig. 5B) . Hence, in addition to increased levels of proteins involved in AD pathology, these results suggest potential contributions of GSK3 activation in cholinergic-induced deficits.
To test the role of GSK3 in the abnormal hippocampal changes in cholinergic-deficient mice, we chronically treated a cohort of aged (11 months old) VAChT NKx2.1-Cre-flox/flox mice with the GSK3 inhibitor AR-A014418 (Fig. 5C ). After 28 days of treatment, we found that VAChT-deficient mice treated with AR-A014418 showed a significant decrease in GSK3 α and β tyrosine phosphorylation compared with VAChT NKx2.1-Cre-flox/flox mice treated with saline ( Fig. 5D) . Increased phosphorylation at Tyr residues 216 or 279 augments GSK3 activity (Hur and Zhou 2010) , and examining GSK3 phosphorylation at these residues has been used to determine the effectiveness of AR-A014418 (Carter et al. 2014; Yadav et al. 2014) . We then assessed some of the key alterations detected in the hippocampus of aged VAChT
NKx2.1-Cre-flox/flox mice. AR-A014418 treatment was able to significantly decrease (n = 4 saline treated, n = 5 AR-A014418 treated, data are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001).
tau T231 hyperphosphorylation and MC1-immunopositive tau in Western blots (Chai et al. 2011; Petry et al. 2014) , by approximately 50% in VAChT NKx2.1-Cre-flox/flox mice compared with saline-treated VAChT NKx2.1-Cre-flox/flox mice. Total levels of tau were unchanged (Fig. 5E ). Immunofluorescence staining (Fig. 5F ) also demonstrated reduced levels of T231 hyperphosphorylated tau in AR-A014418-treated mice. Compared with saline-treated animals, AR-A014418 treatment was able to significantly increase levels of PSD-95 protein (Fig. 5G) . Interestingly, we observed no changes in protein levels of BACE1 following AR-A014418 treatment in aged VAChT NKx2.1-Cre-flox/flox mice (see Supplementary Fig. 5A ). Furthermore, AR-A014418 treatment did not alter the alternative splicing event in the BACE1 gene (see Supplementary Fig. 5A ). Together, these data suggest that the hnRNPA2/B1-mediated alternative splicing and subsequent increase in BACE1 protein level are not mediated by GSK3 activation. Surprisingly, despite reduced levels of hyperphosphorylated tau, 1-month AR-A014418 treatment was unable to decrease the elevated levels of activated caspase-3, (see Supplementary Fig. 5C,D) .
Cholinergic Dysfunction in Human AD Brains
Whether cholinergic genes are expressed in lower levels in human AD brain compared with cognitively alert controls and may contribute to phenotypes detected herein is not fully understood. To examine that, we extracted total RNA from a cohort of 24 adult human temporal gyrus samples collected at the Netherland Brain Bank (sample information in Supplementary Table 2), including 8 sporadic AD patients and 16 from agematched controls. We then profiled AD-related transcript differences by adopting the particularly deep SQUARE™ RNA library construction approach (Hebenstreit and Teichmann 2011) . Of those, 10 885 genes that were expressed showed a significant change. Next, we quantified the levels of those transcripts composing the expanded family of cholinergic regulator genes (Soreq 2015) . Detected cholinergic transcripts showed significantly lower expression levels than other protein-coding genes in the temporal gyrus of AD patients compared with age-matched controls (Fig. 6A) .
Brain samples from a distinct cohort of AD patients (Ostapchenko et al. 2013 ) supported the RNA-Seq analysis results by showing a significant VAChT loss in AD brains compared with age-and sex-matched controls (Fig. 6B ), in agreement with previous observations (Efange et al. 1997; Chen et al. 2011) . Furthermore, the cohort of AD brains exhibited 50% decrease in hnRNPA2/B1 protein levels compared with age-/gender-matched controls (Fig. 6C) , confirming previous results obtained with a distinct AD cohort (Berson et al. 2012) . Additionally, we found a significant positive correlation between VAChT and hnRNPA2/B1 protein levels (Fig. 6D) . AD brain samples also showed drastic increases in tau-Thr231 phosphorylation (Fig. 6E) , which was inversely proportional to the levels of VAChT (Fig. 6F) . Our findings using cholinergic-deficient mice support an intricate timeline whereby cholinergic dysfunction per se precedes and may have strong influence in pathological changes observed in AD. phosphorylation levels. (n = 6, data are mean ± SEM, *P < 0.05, **P < 0.01).
Discussion
We employed transcriptome and biochemical assays on cholinergic-deficient mouse brain samples to explore the impact of long-lasting forebrain cholinergic dysfunction. Whole-genome RNA sequencing demonstrated that cholinergic deficiency modifies expression levels and isoform abundance of several key transcripts related to Alzheimer's disease in the hippocampus of VAChT-deficient mice. Cholinergic-mediated abnormal BACE1 mRNA splicing in VAChT-mutant mice increased BACE1 protein levels and APP processing. Accordingly, cholinergic deficiency caused a 10-fold increase in soluble mouse Aβ peptides, agedependent hippocampal tauopathy, synaptic abnormalities, neuronal inflammation, neuronal vulnerability, and cognitive decline. We also showed that GSK3 activation is critical for cholinergic modulation of tau hyperphosphorylation and synaptic vulnerability. Furthermore, we confirmed that human AD brains present cholinergic dysfunction and showed that it correlates to changes in the levels of hnRNP A2/B1 and hyperphosphorylated tau. Our findings indicate that cholinergic impairments confer widespread hippocampal damage and malfunction. Furthermore, our data support a causal role for cholinergic signaling as a surveillance mechanism controlling hippocampal transcript levels, maintenance of cognitive function, and neuronal viability in mice.
Our RNA sequencing analysis revealed a group of differentially expressed transcripts related to spliceosome regulation in the hippocampus of VAChT Nkx2.1-Cre-flox/flox mice, suggesting that the splicing machinery in these mutants could be altered.
In fact, a significant number of alternative splicing event abnormalities were observed in the hippocampus of VAChT-deficient mice. These results are consistent with previously reported global changes of alternative splicing in the AD brain (Tollervey et al. 2011; Berson et al. 2012; Bai et al. 2013) . Importantly, spliceosome signaling pathway changes can have broad implications for gene regulation (reviewed in (Shin and Manley 2004) ). Alternative splicing in the nervous system is particularly widespread and is essential for multiple aspects of neuronal function (Raj and Blencowe 2015) . However, the signal transduction pathways that regulate splicing are not well known (Shin and Manley 2004) . Our study adds a role for cholinergic signaling in the maintenance of balanced alternative splicing. At least part of the cholinergic control of alternative splicing seems to involve hnRNPA2/B1. We have shown that cholinergic deficiency in the cortex (Berson et al. 2012; Kolisnyk et al. 2013b ) and hippocampus (Fig. 2B ) leads to decreased expression of the hnRNPA2/B1 protein. Related work demonstrated that hnRNPA2/B1 is a cholinergic regulated splicing factor . Importantly, knockdown of hnRNPA2/B1 in cultured hippocampal neurons shifted splicing of BACE1 mRNA towards increased expression of mRNA species coding for the BACE1-501 protein isoform as observed in the hippocampus of VAChT-deficient mice. This splicing change led to increased expression of the BACE1 protein that was accompanied by a pattern of APP processing similar to that observed in commonly used mouse models of AD. The alternative splicing event in BACE1 observed in VAChT-mutant mice is regulated by M1 muscarinic receptors .
Cholinergic tone has been thought to regulate APP processing through muscarinic receptors (Nitsch et al. 1992; Davis et al. 2010) . Specifically, M1 signaling has been shown to regulate the stability of the BACE1 protein (Davis et al. 2010) . BACE1-501 is a more stable and active form of the protein (Mowrer and Wolfe 2008) . Remarkably, BACE1 expression is increased in late-onset AD (Hebert et al. 2008) . Our data suggest potential mechanisms by which cholinergic regulation can affect BACE1 expression and AD pathology. Interestingly, our data suggest that changes in alternative splicing occurs post-transcriptionally and independent of GSK3 signaling. Thus, cholinergic deficiency may affect BACE1 expression differently than previously described in AD, in which GSK3 can regulate BACE1 transcription by increasing promoter activity (Ly et al. 2013) . Our findings promote upstream cholinergic mechanisms as a target for diminishing aberrant APP processing in AD.
In addition to increased levels of soluble Aβ, VAChT
Nkx2.1-Creflox/flox mice also show tau hyperphosphorylation, which destabilizes microtubules and significantly disrupts axonal transport. Tau hyperphosphorylation may also contribute to increased vulnerability leading to neuronal death (Billingsley and Kincaid 1997) . In fact, VAChT-deficient mice show age-dependent increases in hippocampal argyrophilic staining and neuronal death. Oligomeric protein aggregation has been linked to toxicity and to neurodegenerative disorders, including AD (Maeda et al. 2006) . The formation of NFTs alone is insufficient for neurodegeneration, yet oligomeric tau may contribute to neurodegeneration and synaptic loss in AD (Berger et al. 2007; de Calignon et al. 2012) . These observed changes in tau in VAChT-deficient mice (i.e., increased oligomer formation), the associated age-dependent increase in immunoreactivity of activated caspase-3, and ultimately neuronal loss all support a relationship between cholinergic failure and AD-like pathology in mice.
Tau hyperphosphorylation can occur due to the increased activity of GSK3, which subsequently leads to an array of impairments, including disruption of LTP (Hooper et al. 2007 ) and cell death in vitro (Zheng et al. 2002) . GSK3 overactivation is an important hallmark in AD (Hooper et al. 2008) . Thus, the GSK3 overactivation observed in VAChT-mutant mice represents a potential mechanism by which reduced cholinergic activity may have multiple influences in AD pathology in target cells. We tested this hypothesis by pharmacological inhibition of GSK3 in aged VAChT-deficient mice. GSK3 inhibition was able to decrease tau hyperphosphorylation. Also, GSK3 inhibition partially restored PSD95 protein levels, but did not decrease caspase-3 activation. These findings demonstrate that cholinergicinduced changes in tau and in amyloid processing are potentially independent of each other and suggest that cholinergic dysfunction is contributing to the pathological outcomes in these animals by altering multiple pathways. The pharmacological inhibition of GSK3 was tested in mice in which pathology was already present (11-to 12-month-old mice). Hence, further experiments should test longer treatments with the compound or genetic ablation of GSK3 genes in VAChT-deficient mice to comprehensively dissect the contribution of overactive GSK3 in other phenotypes.
Aged VAChT-deficient mice showed a decrease in the number of hippocampal neurons, a result that was not observed in young mutants, suggesting that cholinergic tone may play a role in guarding hippocampal neuronal health. Additionally, aged VAChT-deficient mice showed increased neuroinflammation and reduced number of synapses, which are pathologies observed in AD brains (DeKosky and Scheff 1990; Smale et al. 1995; Rogers and Shen 2000) . Mice with excess acetylcholinesterase, which present decreased cholinergic function, also show neuroinflammation (Shaked et al. 2009 ). Furthermore, similar to our observation, mice lacking the β2 nicotinic receptor subunit show age-dependent loss of hippocampal neurons (Zoli et al. 1999) . Of note, hippocampal neuronal loss is a critical feature in AD, which is not observed in mouse models overexpressing APP and/or presenilin 1 with human AD mutations (Stein and Johnson 2002) . Hence, long-term cholinergic deficiency may model this aspect of AD in a better way. Potential mechanisms involved in cholinergic dysfunction-induced pathology are shown in Figure 7 .
In line with an age-dependent loss of hippocampal neurons, we found that aged VAChT-deficient mice showed significant impairments in their learning strategy in the MWM task. Poor performance and acquisition on the MWM task have been associated with loss of neurons in the hippocampus (Olsen et al. 1994) . This suggests that neuronal loss in the hippocampus has functional consequences in mice as well. In AD brains, we found evidence of cholinergic decline and showed a striking relationship between VAChT levels and tau hyperphosphorylation. Together with the mouse data, these observations support the notion that deficient cholinergic signaling in AD may correlate to key pathological events, including tau hyperphosphorylation.
Our data reveal that cholinergic deficiency can affect a number of transcriptional processes, disturb splicing of key genes, and interfere with protein networks that normally protect neurons. Interestingly, recent work revealed that basal forebrain cholinergic neurons present intraneuronal Aβ accumulation even in young adults, which may contribute to their selective vulnerability in AD (Baker-Nigh et al. 2015) . Cholinergic neurons are thought to be highly dependent on the presence of trophic factors for their optimal function and survival (Naumann et al. 2002; Boskovic et al. 2014) , which may also contribute to their demise. Regardless of the mechanisms for increased cholinergic vulnerability in AD, it seems that cholinergic dysfunction persisting for a long period is highly related to hippocampal pathology and amyloid accumulation (Teipel et al. 2014 ).
In short, our results suggest that long-term cholinergic failure per se, which we model by disrupting synaptic cholinergic function, can trigger AD-like pathology in mice. More importantly, we find that long-term cholinergic deficiency leads to age-dependent cognitive decline that is related to neuronal death, a key feature of late-onset AD that is not modeled in mice overexpressing human genes with AD-related mutations. Our experiments provide a mechanism to explain how decreased cholinergic tone, for example due to long-term use of anticholinergic drugs, could lead to increased risk of dementia (Gray et al. 2015) , which may depend on global changes of RNA metabolism, including alternative splicing and gene expression. It remains to be determined whether rescuing cholinergic function prior to development of AD could have an impact in the risk of dementia or AD-related pathology. However, it is noteworthy that recent observations in potential prodromal AD-affected individuals indicate that cholinesterase inhibition decreases the rate of hippocampal atrophy by 45% during 1-year treatment (Dubois et al. 2015) . Our data point towards cholinergic signaling being a global mediator of several distinct processes that when dysfunctional lead to pathology. Developing effective strategies to reverse the cholinergic deficits in the AD brain may therefore prove to be more fruitful than specific therapies based on reversing the individual processes it regulates.
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